Aug. 23, 2016

Options Backtesting Results

Historical average return: +$86.50 (backtested over 1.5 years)
Historical success probability: 53.9%

Summary

An options backtest shows that the cost to purchase put spreads on biotechnology ETF XBI is near its lowest level since early 2015. Hedgers worried about further turmoil in the biotech sector would find these options attractive due to their inexpensive current pricing and positive historical returns in the backtest.

Sign up to view the full trade details and options backtesting analysis